Business
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload platformALX2004, the company’s first ADC, was fully designed and developed in-house by ALX Oncology scientistsCompany expects to initiate Phase 1 clinical trials of ALX2004 in mid-2025, with initial safety data available in 1H 2026 SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- ALX Oncology
About this update from Alx Oncology Holdings Inc.
[{"type":"image","alt":"ALX Oncology","displaySize":"","headline":null,"caption":"ALX Oncology","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":195,"url":"https://media.zenfs.com/en/globenewswire.com/470f956a3deddaf81b04c64bb1806e3d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tBYkx9_bHbgV6zgiof22Rw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/470f956a3deddaf81b04c64bb1806e3d","width":300,"height":195}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload platform","length":200,"tagName":"p"}]},{"val":[{"type":"text","content":"ALX2004, the company’s first ADC, was fully designed and developed in-house by ALX Oncology scientists","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"Company expects to initiate Phase 1 clinical trials of ALX2004 in mid-2025, with initial safety data available in 1H 2026","length":121,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":423,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced receipt of U.S. Food and Drug Administration (FDA) clearance for the Investigational New Drug (IND) application for ALX2004, the company’s potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of epidermal growth factor receptor (EGFR)-expressing solid tumors. Based on this clearance, ALX Oncology will initiate a single-agent dose-escalation and expansion Phase 1 clinical trial for ALX2004 in mid-2025.","length":724,"tagName":"p"},{"type":"text","content":"“Clinical advancement of our first ADC and the first drug candidate developed on our proprietary linker-payload platform is an important milestone in our mission to deliver breakthrough therapies that will help transform the future of cancer treatment,” said Jason Lettmann, Chief Executive Officer at ALX Oncology. “We meticulously designed all aspects of ALX2004...